India, April 14 -- Shares of Verve Therapeutics, Inc. (VERV) gained over 29% on Monday morning after the company announced positive initial data from the Heart-2 phase 1b clinical trial of VERVE-102.
VERV is currently trading at $4.2099, up $0.9499 or 29.1014%, on a huge volume of 17 million shares, above average volume of 1.6 million, on the Nasdaq. The stock opened its trading at $4.1100 after closing Friday at $3.2600. The stock has traded between $2.8650 and $9.3050 in the past 52-week period.
Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102.
The Heart-2 Phase 1b clinical trial is e...